Drugs / MILREBRUTINIB
MILREBRUTINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05602363 | Aug 2023 → Sep 2027 expected | Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma +1 | Carna Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MILREBRUTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5077961 ↗ |
| Known as | AS-1763 | “oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL” NCT05602363 ↗ |
| Known as | Docirbrutinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05602363 ↗ |
| Modality | Small molecule | — CHEMBL5077961 ↗ |
| Route | Oral | “oral tablet, twice daily” NCT05602363 ↗ |